Table 1. Clinical and pathological features of breast tumors analyzed by stem-loop reverse transcription-quantitative PCR in TaqMan low-density arrays.
| Patient | Age (years) | Clinical stage | Tumor grade | Classification | Tumor size (mm) | Histological subtype | HER2 | ER | PR |
|---|---|---|---|---|---|---|---|---|---|
| 15 | 45 | II | 2 | HER2 | 35 | Infiltrating ductal carcinoma | + | − | + |
| 30 | 41 | I | 2 | Luminal B | 20 | In situ ductal carcinoma | + | + | + |
| 75 | 50 | IIB | 2 | HER2 | 25 | Infiltrating ductal carcinoma | + | − | − |
| 76 | 49 | IIB | 3 | HER2 | 20 | Infiltrating ductal carcinoma | + | − | − |
| 78 | 81 | IIIB | 3 | HER2 | 47 | Infiltrating ductal carcinoma | + | − | − |
| 85 | 47 | IIA | 3 | HER2 | 27 | Infiltrating ductal carcinoma | + | − | + |
| 88 | 63 | I | ND | Luminal A | 15 | Infiltrating ductal carcinoma | + | + | − |
| 105 | 39 | IIIC | 2 | HER2 | 23 | Infiltrating ductal carcinoma | + | − | + |
| 191 | 55 | IIB | ND | HER2 | 39 | Infiltrating ductal carcinoma | + | − | − |
HER2, Human epidermal receptor 2. ER, Estrogen receptor. PR, Progesterone receptor. ND, Not determined.